Genomic testing in cancer: Patient knowledge, attitudes, and expectations

Phillip S. Blanchette, Anna Spreafico, Fiona A. Miller, Kelvin Chan, Jessica Bytautas, Steve Kang, Philippe L. Bedard, Andrea Eisen, Larissa Potanina, Jack Holland, Suzanne Kamel-Reid, John Douglas Mcpherson, Albiruni R. Razak, Lillian L. Siu

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

BACKGROUND Genomic testing in cancer (GTC) characterizes genes that play an important role in the development and growth of a patient's cancer. This form of DNA testing is currently being studied for its ability to guide cancer therapy. The objective of the current study was to describe patients' knowledge, attitudes, and expectations toward GTC. METHODS A 42-item self-administered GTC questionnaire was developed by a multidisciplinary group and patient pretesting. The questionnaire was distributed to patients with advanced cancer who were referred to the Princess Margaret Cancer Center for a phase 1 clinical trial or GTC testing. RESULTS Results were reported from 98 patients with advanced cancer, representing 66% of the patients surveyed. Seventy-six percent of patients were interested in learning more about GTC, and 64% reported that GTC would significantly improve their cancer care. The median score on a 12-item questionnaire to assess knowledge of cancer genomics was 8 of 12 items correct (67%; interquartile range, 7-9 of 12 items correct [58%-75%]). Scores were associated significantly with patients' education level (P<.0001). Sixty-six percent of patients would consent to a needle biopsy, and 39% would consent to an invasive surgical biopsy if required for GTC. Only 48% of patients reported having sufficient knowledge to make an informed decision to pursue GTC whereas 34% of patients indicated a need for formal genetic counseling. CONCLUSIONS Patients with advanced cancer are motivated to participate in GTC. Patients require further education to understand the difference between somatic and germline mutations in the context of GTC. Educational programs are needed to support patients interested in pursuing GTC.

Original languageEnglish (US)
Pages (from-to)3066-3073
Number of pages8
JournalCancer
Volume120
Issue number19
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Neoplasms
Clinical Trials, Phase I
Aptitude
Germ-Line Mutation
Neoplasm Genes
Genetic Counseling
Needle Biopsy
Patient Education
Genomics
Growth and Development
Learning
Biopsy
Education
DNA
Surveys and Questionnaires

Keywords

  • attitude
  • cancer
  • genomic testing
  • knowledge

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Blanchette, P. S., Spreafico, A., Miller, F. A., Chan, K., Bytautas, J., Kang, S., ... Siu, L. L. (2014). Genomic testing in cancer: Patient knowledge, attitudes, and expectations. Cancer, 120(19), 3066-3073. https://doi.org/10.1002/cncr.28807

Genomic testing in cancer : Patient knowledge, attitudes, and expectations. / Blanchette, Phillip S.; Spreafico, Anna; Miller, Fiona A.; Chan, Kelvin; Bytautas, Jessica; Kang, Steve; Bedard, Philippe L.; Eisen, Andrea; Potanina, Larissa; Holland, Jack; Kamel-Reid, Suzanne; Mcpherson, John Douglas; Razak, Albiruni R.; Siu, Lillian L.

In: Cancer, Vol. 120, No. 19, 2014, p. 3066-3073.

Research output: Contribution to journalArticle

Blanchette, PS, Spreafico, A, Miller, FA, Chan, K, Bytautas, J, Kang, S, Bedard, PL, Eisen, A, Potanina, L, Holland, J, Kamel-Reid, S, Mcpherson, JD, Razak, AR & Siu, LL 2014, 'Genomic testing in cancer: Patient knowledge, attitudes, and expectations', Cancer, vol. 120, no. 19, pp. 3066-3073. https://doi.org/10.1002/cncr.28807
Blanchette PS, Spreafico A, Miller FA, Chan K, Bytautas J, Kang S et al. Genomic testing in cancer: Patient knowledge, attitudes, and expectations. Cancer. 2014;120(19):3066-3073. https://doi.org/10.1002/cncr.28807
Blanchette, Phillip S. ; Spreafico, Anna ; Miller, Fiona A. ; Chan, Kelvin ; Bytautas, Jessica ; Kang, Steve ; Bedard, Philippe L. ; Eisen, Andrea ; Potanina, Larissa ; Holland, Jack ; Kamel-Reid, Suzanne ; Mcpherson, John Douglas ; Razak, Albiruni R. ; Siu, Lillian L. / Genomic testing in cancer : Patient knowledge, attitudes, and expectations. In: Cancer. 2014 ; Vol. 120, No. 19. pp. 3066-3073.
@article{fae622e726f443299c8af6a79b5f61cf,
title = "Genomic testing in cancer: Patient knowledge, attitudes, and expectations",
abstract = "BACKGROUND Genomic testing in cancer (GTC) characterizes genes that play an important role in the development and growth of a patient's cancer. This form of DNA testing is currently being studied for its ability to guide cancer therapy. The objective of the current study was to describe patients' knowledge, attitudes, and expectations toward GTC. METHODS A 42-item self-administered GTC questionnaire was developed by a multidisciplinary group and patient pretesting. The questionnaire was distributed to patients with advanced cancer who were referred to the Princess Margaret Cancer Center for a phase 1 clinical trial or GTC testing. RESULTS Results were reported from 98 patients with advanced cancer, representing 66{\%} of the patients surveyed. Seventy-six percent of patients were interested in learning more about GTC, and 64{\%} reported that GTC would significantly improve their cancer care. The median score on a 12-item questionnaire to assess knowledge of cancer genomics was 8 of 12 items correct (67{\%}; interquartile range, 7-9 of 12 items correct [58{\%}-75{\%}]). Scores were associated significantly with patients' education level (P<.0001). Sixty-six percent of patients would consent to a needle biopsy, and 39{\%} would consent to an invasive surgical biopsy if required for GTC. Only 48{\%} of patients reported having sufficient knowledge to make an informed decision to pursue GTC whereas 34{\%} of patients indicated a need for formal genetic counseling. CONCLUSIONS Patients with advanced cancer are motivated to participate in GTC. Patients require further education to understand the difference between somatic and germline mutations in the context of GTC. Educational programs are needed to support patients interested in pursuing GTC.",
keywords = "attitude, cancer, genomic testing, knowledge",
author = "Blanchette, {Phillip S.} and Anna Spreafico and Miller, {Fiona A.} and Kelvin Chan and Jessica Bytautas and Steve Kang and Bedard, {Philippe L.} and Andrea Eisen and Larissa Potanina and Jack Holland and Suzanne Kamel-Reid and Mcpherson, {John Douglas} and Razak, {Albiruni R.} and Siu, {Lillian L.}",
year = "2014",
doi = "10.1002/cncr.28807",
language = "English (US)",
volume = "120",
pages = "3066--3073",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "19",

}

TY - JOUR

T1 - Genomic testing in cancer

T2 - Patient knowledge, attitudes, and expectations

AU - Blanchette, Phillip S.

AU - Spreafico, Anna

AU - Miller, Fiona A.

AU - Chan, Kelvin

AU - Bytautas, Jessica

AU - Kang, Steve

AU - Bedard, Philippe L.

AU - Eisen, Andrea

AU - Potanina, Larissa

AU - Holland, Jack

AU - Kamel-Reid, Suzanne

AU - Mcpherson, John Douglas

AU - Razak, Albiruni R.

AU - Siu, Lillian L.

PY - 2014

Y1 - 2014

N2 - BACKGROUND Genomic testing in cancer (GTC) characterizes genes that play an important role in the development and growth of a patient's cancer. This form of DNA testing is currently being studied for its ability to guide cancer therapy. The objective of the current study was to describe patients' knowledge, attitudes, and expectations toward GTC. METHODS A 42-item self-administered GTC questionnaire was developed by a multidisciplinary group and patient pretesting. The questionnaire was distributed to patients with advanced cancer who were referred to the Princess Margaret Cancer Center for a phase 1 clinical trial or GTC testing. RESULTS Results were reported from 98 patients with advanced cancer, representing 66% of the patients surveyed. Seventy-six percent of patients were interested in learning more about GTC, and 64% reported that GTC would significantly improve their cancer care. The median score on a 12-item questionnaire to assess knowledge of cancer genomics was 8 of 12 items correct (67%; interquartile range, 7-9 of 12 items correct [58%-75%]). Scores were associated significantly with patients' education level (P<.0001). Sixty-six percent of patients would consent to a needle biopsy, and 39% would consent to an invasive surgical biopsy if required for GTC. Only 48% of patients reported having sufficient knowledge to make an informed decision to pursue GTC whereas 34% of patients indicated a need for formal genetic counseling. CONCLUSIONS Patients with advanced cancer are motivated to participate in GTC. Patients require further education to understand the difference between somatic and germline mutations in the context of GTC. Educational programs are needed to support patients interested in pursuing GTC.

AB - BACKGROUND Genomic testing in cancer (GTC) characterizes genes that play an important role in the development and growth of a patient's cancer. This form of DNA testing is currently being studied for its ability to guide cancer therapy. The objective of the current study was to describe patients' knowledge, attitudes, and expectations toward GTC. METHODS A 42-item self-administered GTC questionnaire was developed by a multidisciplinary group and patient pretesting. The questionnaire was distributed to patients with advanced cancer who were referred to the Princess Margaret Cancer Center for a phase 1 clinical trial or GTC testing. RESULTS Results were reported from 98 patients with advanced cancer, representing 66% of the patients surveyed. Seventy-six percent of patients were interested in learning more about GTC, and 64% reported that GTC would significantly improve their cancer care. The median score on a 12-item questionnaire to assess knowledge of cancer genomics was 8 of 12 items correct (67%; interquartile range, 7-9 of 12 items correct [58%-75%]). Scores were associated significantly with patients' education level (P<.0001). Sixty-six percent of patients would consent to a needle biopsy, and 39% would consent to an invasive surgical biopsy if required for GTC. Only 48% of patients reported having sufficient knowledge to make an informed decision to pursue GTC whereas 34% of patients indicated a need for formal genetic counseling. CONCLUSIONS Patients with advanced cancer are motivated to participate in GTC. Patients require further education to understand the difference between somatic and germline mutations in the context of GTC. Educational programs are needed to support patients interested in pursuing GTC.

KW - attitude

KW - cancer

KW - genomic testing

KW - knowledge

UR - http://www.scopus.com/inward/record.url?scp=84908546322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908546322&partnerID=8YFLogxK

U2 - 10.1002/cncr.28807

DO - 10.1002/cncr.28807

M3 - Article

C2 - 24962202

AN - SCOPUS:84908546322

VL - 120

SP - 3066

EP - 3073

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 19

ER -